NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University WESTON, Fla. and NASHVILLE, Tenn., May 15, 2018 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) and Vanderbilt University Medical Center today announced filing of an Investigational New Drug...

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data NEW YORK, July 05, 2017 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, today announced promising results from its Phase 1b pertussis vaccine clinical...

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups...